Begin main content

CADTH pan-Canadian Oncology Drug Review

pCODR RSS feed

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Pembrolizumab (Keytruda) for Non-Squamous Non-Small Cell Lung Cancer
(Notification to Implement Issued as of June 17, 2019)

Dacomitinib (Vizimpro) for Non-Small Cell Lung Cancer
(Notification to Implement Issued as of June 17, 2019)

Venetoclax (Venclexta) in combo Rituximab for Chronic Lymphocytic Leukemia
(Notification to Implement Issued as of June 17, 2019)

Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer
(Open for Input on Submission until June 25, 2019)

Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma
(Pending Submission as of June 10, 2019)

Crizotinib (Xalkori) for ROS1-Positive Non-Small Cell Lung Cancer
(Notification to Implement Issued as of June 7, 2019)

Trastuzumab Emtansine (Kadclya) for Early Breast Cancer
(Pending Submission as of June 3, 2019)

Pembrolizumab (Keytruda) for Melanoma Adjuvant Treatment
(Open for Feedback on Recommendation until June 14, 2019)

Lutetium Lu 177 dotatate (Lutathera) for Gastroenteropancreatic Neuroendocrine Tumors
(Open for Feedback on Recommendation until June 14, 2019)

Brigatinib (Alunbrig) for Non-Small Cell Lung Cancer
(Open for Feedback on Recommendation until June 14, 2019)

Lenalidomide (Revlimid) in combination with Bortezomib and Dexamethasone for Multiple Myeloma
(Open for Feedback on Recommendation until June 14, 2019)

Find a Drug Review